TriRx to Acquire Merck’s MSD Sante Animale Manufacturing Facility

September 1, 2020
BioPharm International Editors

The facility offers office, production, sampling, and warehouse space and delivers products to all major global markets.

TriRx Pharmaceutical Services, a contract development and manufacturing organization (CDMO), announced on Sept. 1, 2020 that it has acquired the operations and ownership of MSD Sante Animale’s, a division of Merck & Co, manufacturing site located in Segré, France.

The facility offers office, production, sampling, and warehouse space and delivers products to all major global markets, a company press release said. The site currently houses more than 90 employees and manufactures veterinary products.

“We are excited to welcome the Segré team to the TriRx family and to partner with MSD Animal Health to continue to provide important products to the market,” said Timothy C. Tyson, chairman and CEO of TriRx, in the press release. “This transaction allows us to continue our expansion as a global CDMO while assuring continuity of supply of animal health products from the Segré site. The site’s history of exceptional performance and the world-class knowledge and experience of the site staff expand TriRx service offerings into sterile suspensions and liquids and non-sterile ointments and liquids.”

Source: TriRx